CoSyne Therapeutics
CoSyne Therapeutics is a vertically integrated AI drug discovery company dedicated to accelerating precision medicine for under-served brain diseases. By leveraging polymathic AI and deep biological insights, they develop targeted combination therapies that address complex neurological conditions with unprecedented speed and accuracy, offering hope to patients in critical need.
Founders
Neurologist with a background in biomedical entrepreneurship. Studied neuroscience at Cambridge and clinical medicine at Oxford. Graduated top of his year and was the first medical student in Oxford history to be awarded merits in every exam. Top ranking applicant to London academic medical training and was the highest scoring applicant to neurology specialist training in the UK.
Louwai Muhammed
CEO, Co-Founder
PhD from Imperial College London in Computational Systems Biology. Over 7-years of research on brain tumours, glioma microenvironments and vasculature, cancer genetics and pathways of malignant transformation. Studied neuroscience in Karolinska Institute, medical science in Uppsala University and was ranked first in genetics at University of Tartu, graduating cum laude
Liisi Laaniste
CSO, Co-Founder
Michael is co-founder and CMO of CoSyne Therapeutics. Academically, he is Professor of Neurology and Genomic Medicine at Imperial College and Head of the Division of Neurology at Imperial. Michael is expert in translational systems genetics and computational biology for drug discovery and causal inference. He has extensive experience of working with industry, including research collaborations and clinical trial design (e.g., Roche, UCB, GSK) and scientific advisory boards. In his spare time, Michael is a Committee Member for Motor Sport UK and races nationally in the Porsche Club Championship